Last Updated: May, 2026
Trusted by 200+ Clients
Compare & Choose the Right Report Version for You
How to Order Your Report?
The report provides a detailed analysis essential for establishing a Baricitinib production plant. It encompasses all critical aspects necessary for Baricitinib production, including the cost of Baricitinib production, Baricitinib plant cost, Baricitinib production costs, and the overall Baricitinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Baricitinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Baricitinib is an inhibitor of Janus kinase used to treat moderate-to-severe rheumatoid arthritis. It is a member of the class of drugs called disease-modifying antirheumatic drugs (DMARDs) and inhibits JAK1 and JAK2 activity, which reduces JAK-mediated immune responses and inflammation. Adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more TNF blockers may benefit from treatment with Baricitinib.
The procurement of Baricitinib is influenced by its application in the pharmaceutical and medical industries to treat moderate-to-severe rheumatoid arthritis. The demand for Baricitinib is also increasing due to the rising cases of rheumatoid arthritis. The majority of demand comes from the aging population since they have a higher chance of acquiring rheumatoid arthritis. It is recommended for the management of moderate-to-severe atopic dermatitis in adult patients who are suitable for systemic therapy. It is also recommended for the treatment of coronavirus disease 2019 (COVID-19) and has recently been approved as a therapy for adult patients with severe alopecia areata.
Baricitinib can be taken either on its own or in conjunction with other DMARDs, such as methotrexate, which increases its demand. In general, the industrial Baricitinib procurement directly depends on its usage in the pharmaceutical and medical industries, rising cases of rheumatoid arthritis, the aging population, usage with other DMARDs, its wide range of applications, increasing healthcare awareness among people, cost-efficiency, rising technological advancements, research & development, and regulatory approvals.
According to the Baricitinib production plant project report, the key raw material used in the production of Baricitinib includes 1-Boc-3-azetidinone.
The extensive Baricitinib production cost report consists of the following major industrial production process:
Baricitinib, commercially known as Olumiant, is a white to off-white powder, having the molecular formula C16H17N7O2S and a molecular weight of 371.4 g/mol. It has a boiling point of around 707.2 °C. It has a water solubility of 0.357 mg/mL. The value of its log P is 1.08. The value of its dissociation constant, pKa, is 13.89. It is a pyrrolopyrimidine, a sulfonamide, a nitrile, a member of the pyrazoles, and a member of the azetidines. It is an inhibitor of Janus kinase inhibitor used to treat moderate-to-severe rheumatoid arthritis.
Baricitinib Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Baricitinib |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) |
| Pricing and Purchase Options | Basic: US$ 2499 Premium: US$ 3499 Enterprise: US$ 4799 |
| Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we not only focus on optimizing the should cost of production for Baricitinib but also provide our clients with extensive intel and rigorous information on every aspect of the production process. By utilizing a comprehensive cost model, we help you break down expenses related to raw materials, labor, and technology, offering clear pathways to savings. We also assist in evaluating the capital expenditure (CAPEX) and operating expenses (OPEX), which are often measured as cost per unit of production, such as USD/MT, ensuring that your financial planning is aligned with industry benchmarks.
We offer valuable insights on the top technology providers, in-depth supplier database, and best manufacturers, helping you make informed decisions to improve efficiency. Additionally, we design the most feasible layout for your production needs, ensuring the entire process runs smoothly. By minimizing the cash cost of production, we ensure that you stay competitive while securing long-term profitability in the growing Baricitinib market. Partnering with Procurement Resource guarantees that every aspect of your production is cost-efficient, advanced, and tailored to your specific requirements.
Vishakha Agrawal
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
